# CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children

> **NCT02204917** · PHASE1,PHASE2 · COMPLETED · sponsor: **Kassa Darge** · enrollment: 31 (actual)

## Conditions studied

- Vesico-Ureteral Reflux

## Interventions

- **DRUG:** OPTISON

## Key facts

- **NCT ID:** NCT02204917
- **Lead sponsor:** Kassa Darge
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07
- **Primary completion:** 2016-03
- **Final completion:** 2017-03
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2018-11-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02204917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02204917, "CeVUS With Intravesical Administration of OPTISON TM (Trademark) in Children". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT02204917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*